Abstract
BRAF mutation is occurred in about 8% of human malignancy, including 40-60% in malignant melanoma, 50% in thyroid papillary cancer, 10% in colorectal cancer, and a few percent of non-small cell lung cancer. Activated mutation of BRAF is mainly p. V600E mutation. BRAF inhibitors were initially developed in malignant melanoma. In a recent few years, BRAF inhibitor-based therapy has been developed also in other cancers such as lung cancer and colorectal cancer. I herein describe the current status of development of new therapeutic strategies for S/MF-mutated cancer, particularly BRAF-targeting therapy.
Original language | English |
---|---|
Pages (from-to) | 861-865 |
Number of pages | 5 |
Journal | Japanese Journal of Cancer and Chemotherapy |
Volume | 48 |
Issue number | 7 |
Publication status | Published - 2021 Jul |
Keywords
- Anti-EGFR-antibody
- BRAF inhibitor
- BRAF mutation
- MEK inhibitor
ASJC Scopus subject areas
- Medicine(all)